Junshi Biosciences' Toripalimab Receives Full Approval for Urothelial Carcinoma; Phase III Data Shows OS Nearly Doubled
nashnova research
Junshi Biosciences' Toripalimab (拓益®) has converted its conditional approval for urothelial carcinoma into full regulatory approval, backed by Phase III data showing overall survival extended from 16.9 to 31.5 months — this removes all promotional restrictions on the indication and gives long-term commercialization both a clinical and regulatory foundation.
What does "full approval" change versus "conditional approval"?
In 2021, Toripalimab received conditional approval — a mechanism where China's NMPA allows a drug to launch early while the company must submit confirmatory data later. Commercial promotion was restricted.
Full approval means the confirmatory Phase III data have cleared regulatory review, and the drug's efficacy and safety are fully recognized.
This means → hospital procurement, national reimbursement negotiations, and academic promotion are no longer held back by a "conditional" label. Commercialization enters an unrestricted phase.
What did the Phase III trial actually deliver?
Core design: Toripalimab plus disitamab vedotin — an ADC (antibody-drug conjugate, a technology that delivers chemotherapy directly to tumor cells) — versus standard platinum-based chemotherapy, head to head.
Progression-free survival doubled: 13.1 months vs. 6.5 months (HR = 0.36, p < 0.0001). Overall survival nearly doubled: 31.5 months vs. 16.9 months (HR = 0.54, p < 0.0001).
Objective response rate hit 76.1% vs. 50.2%; duration of response reached 14.6 months vs. 5.6 months. In plain terms = more patients saw their tumors shrink, and the shrinkage lasted nearly three times as long.
Why did this data set land in the NEJM?
The results were published in the *New England Journal of Medicine* (NEJM, the highest-impact general medical journal globally) in October 2025, with a simultaneous oral presentation at the ESMO Presidential Symposium.
This reflects top-tier international academic recognition of the trial's dual-endpoint positive results — both PFS and OS reached statistical significance.
This means → the win is not just a domestic regulatory milestone; it is a credibility endorsement for Toripalimab in the global oncology community.
Where does Toripalimab sit in Junshi's product portfolio?
Toripalimab is Junshi Bio's flagship PD-1 monoclonal antibody — an immune checkpoint inhibitor that helps the immune system re-identify and attack tumors. It now holds 13 approved indications in mainland China, of which 12 are covered by the national reimbursement list.
It is the only anti-PD-1 antibody on the reimbursement list covering renal cell carcinoma, triple-negative breast cancer, and melanoma simultaneously.
This means → Toripalimab's differentiation lies not in any single cancer type but in indication breadth — each new full approval raises the commercial ceiling another notch.
What does this milestone mean for investors?
Full approval + NEJM publication + ESMO oral presentation — three signals stacked together — form the key reference point for the market to assess Toripalimab's long-term commercial potential in urothelial cancer.
In plain terms = the regulator says "the data check out," a top journal says "the science holds up." What comes next is volume ramp speed and reimbursement negotiation leverage.
On the risk side: the PD-1 space is fiercely competitive. Whether Toripalimab can convert its academic edge into market share still hinges on pricing strategy and channel execution.
市场有风险，内容仅供研究参考，不构成投资建议。